Summary
Isradipine, a new calcium antagonist, was administered to 51 Pakistani patients with hypertension (36 women, 15 men; mean age 47 years) over an 8-week period. Mean sitting systolic, and sitting and standing diastolic blood pressure was significantly reduced, and mean standing systolic blood pressure tended to decrease. Laboratory values, and both sitting and standing heart rates were not significantly affected by isradipine treatment. At the end of 8 weeks, 41.2% of patients were receiving isradipine 1.25mg twice daily, and 58.8% were receiving 2.5mg twice daily. Isradipine was found to be effective and well tolerated in Pakistani patients with mild to moderate hypertension.
Similar content being viewed by others
References
Dahlöf B. Hemodynamic response, safety and efficacy of isradipine in the treatment of essential hypertension. American Journal of Medicine 86(4A): 19–26, 1989
Krusell LR, Jespersen LT, Schmitz A, Thomsen K, Pedersen OL. Repetitive natriuresis and blood pressure: long term calcium entry blockade with isradipine. Hypertension 10: 577–581, 1987
Lederballe Pedersen O, Krusell LR, Sihm I, Jespersen L. Long term effects of isradipine on blood pressure and renal function. American Journal of Medicine 86(4A): 15–18, 1989
Persson B, Andersson OK, Wysocki M, Hedner T, Aurell M. Renal and hemodynamic effects of isradipine in essential hypertension. American Journal of Medicine 86(4A): 60–64, 1989
Zanchetti A, Leonetti G. Natriuretic effects of calcium antagonists. Journal of Cardiovascular Pharmacology 7(Suppl. 4): S33–S37, 1985
Zanchetti A, Leonetti G. Discussion on the natriuretic effects of calcium antagonists. Journal of Cardiovascular Pharmacology 10(Suppl. I): S161–S164, 1987
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zubair, M., Karim, S. & Hussain, S. Isradipine in Asian Patients with Hypertension. Drugs 40 (Suppl 2), 26–29 (1990). https://doi.org/10.2165/00003495-199000402-00008
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199000402-00008